Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval
25 Setembro 2023 - 7:12PM
Dow Jones News
By Stephen Nakrosis
Ultragenyx Pharmaceutical said Evkeeza was approved by Health
Canada to help treat certain patients with high cholesterol.
Evkeeza was discovered and developed by Regeneron
Pharmaceuticals, which solely commercializes the product in the
U.S., Ultragenyx said, adding it is responsible for
commercialization efforts in countries outside of the U.S.
Evkeeza, or evinacumab, was approved as an adjunct to diet and
other therapies to treat adult and pediatric patients five and
older who suffer from homozygous familial hypercholesterolemia.
The U.S. National Institutes of Health said the rare
life-threatening condition can cause "elevated circulating levels
of low-density lipoprotein cholesterol and accelerated, premature
atherosclerotic cardiovascular disease."
The treatment will be commercially available in Canada as of
Nov. 25, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 25, 2023 17:57 ET (21:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
